BrainStorm Awarded Additional $735K Non-Dilutive Grant for 2015 from Israel's Office of the Chief Scientist

BrainStorm Cell Therapeutics Inc.

today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded an additional grant of approximately $735,000 from Israel's Office of the Chief Scientist (OCS). This grant, the second this year, brings the total awarded by OCS to Brainstorm for 2015 activities to approximately $1.8 million (approximately NIS7 million).  As reported by the company on December 15, 2014,  this is the eighth year that BrainStorm has been in receipt of grant support from the Office of the Chief Scientist, which is part of the Ministry of Economy Program to support innovative technologies in Israel. The funds will support the development NurOwn™, BrainStorm's innovative mesenchymal stem cell-based platform for treating neurodegenerative diseases. NurOwn™ is currently being investigated in a Phase 2 clinical program in amyotrophic lateral sclerosis (ALS). BrainStorm's CEO Chaim Lebotivs, commented "We are proud that the OCS has recognized the importance and priority of our innovative R&D activities, and are grateful for its continual enthusiastic support. This is the